STOCK TITAN

NovaBridge Biosciences officer buys 230K shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Mark Arnold Hagler, NovaBridge Biosciences’ Chief Commercial Officer, purchased 46,000 ordinary shares on November 17, 2026, at a reported $0.3430 per share. On November 18, he purchased 184,000 ordinary shares at a reported $0.3810 per share. Footnotes associate the purchases with 20,000 and 80,000 ADSs, respectively; each 10 ADSs represent 23 ordinary shares. The cited ADS prices were $0.79 and a weighted average of $0.8758, with the November 18 ADS purchases ranging from $0.84 to $0.90. No Rule 10b5-1 plan is reported.

Insider Hagler Mark Arnold
Role Chief Commercial Officer
Bought 230,000 shs ($86K)
Type Security Shares Price Value
Purchase Ordinary Shares F1, F4, F5 184,000 $0.381 $70K
Purchase Ordinary Shares F1, F2, F3 46,000 $0.343 $16K
Holdings After Transaction: Ordinary Shares — 460,000 shares (Direct)
Footnotes (5)
  1. F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
  2. F2. Reported securities are represented by 20,000 ADSs.
  3. F3. The price reported in Column 4 represents the converted sales price of the ADSs of $0.79.
  4. F4. Reported securities are represented by 80,000 ADSs.
  5. F5. The price reported in Column 4 represents the converted weighted average price per ADS of $0.8758. These ADSs were purchased in multiple transactions at prices ranging from $0.84 to $0.90 per ADS, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Ordinary shares purchased 46,000 shares November 17, 2026
Reported purchase price $0.3430 per share November 17, 2026
Ordinary shares purchased 184,000 shares November 18, 2026
Reported purchase price $0.3810 per share November 18, 2026
ADSs represented 20,000 ADSs November 17 purchase
ADS price $0.79 per ADS November 17 purchase
ADSs represented 80,000 ADSs November 18 purchase
Weighted average ADS price $0.8758 per ADS November 18 purchase; ADS prices ranged from $0.84 to $0.90
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBP ordinary shares did Mark Arnold Hagler buy?

He purchased 230,000 ordinary shares across two transactions: 46,000 on November 17, 2026, and 184,000 on November 18, 2026. The purchases were reported as direct holdings.

What prices did Mark Arnold Hagler pay for NBP shares?

The reported ordinary-share prices were $0.3430 and $0.3810 per share, for the November 17 and November 18 purchases, respectively. Footnotes cite ADS prices of $0.79 and a weighted average of $0.8758, respectively; the November 18 ADS purchases ranged from $0.84 to $0.90. Each 10 ADSs represent 23 ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hagler Mark Arnold

(Last)(First)(Middle)
C/O NOVABRIDGE BIOSCIENCES
2440 RESEARCH BOULEVARD, SUITE 400

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)11/17/2026P46,000(2)A$0.343(3)276,000D
Ordinary Shares(1)11/18/2026P184,000(4)A$0.381(5)460,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. Reported securities are represented by 20,000 ADSs.
3. The price reported in Column 4 represents the converted sales price of the ADSs of $0.79.
4. Reported securities are represented by 80,000 ADSs.
5. The price reported in Column 4 represents the converted weighted average price per ADS of $0.8758. These ADSs were purchased in multiple transactions at prices ranging from $0.84 to $0.90 per ADS, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Charles Silberstein as attorney-in-fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading